Therapeutic effects of pegylated-interferon-α2a in a mouse model of multiple sclerosis

Sanaz Afraei; Reza Sedaghat; Farzaneh Tofighi Zavareh; Zahra Aghazadeh; Parvin Ekhtiari; Gholamreza Azizi; Abbas Mirshafiey

doi:10.5114/ceji.2018.74868

eISSN: 1644-4124
ISSN: 1426-3912

Central European Journal of Immunology

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

1/2018
vol. 43

Send email

Copy url:

abstract:

Experimental immunology

Therapeutic effects of pegylated-interferon-α2a in a mouse model of multiple sclerosis

Sanaz Afraei

,

Reza Sedaghat

,

Farzaneh Tofighi Zavareh

,

Zahra Aghazadeh

,

Parvin Ekhtiari

,

Gholamreza Azizi

,

Abbas Mirshafiey

(Centr Eur J Immunol 2018; 43 (1): 9-17)

DOI: https://doi.org/10.5114/ceji.2018.74868

Online publish date: 2018/03/30

View full text Get citation

PlumX metrics:

Introduction
Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS). EAE is mainly mediated by adaptive and innate immune responses that lead to an inflammatory demyelination and axonal damage. The aim of the present research was to examine the therapeutic efficacy of Peg interferon alpha 2a (Peg-IFN α-2a) as a serine protease inhibitor on EAE model.

Material and methods
EAE induction was performed in female C57BL/6 mice by myelin oligodendrocyte glycoprotein (35-55) (MOG_35-55) in Complete Freund’s Adjuvant (CFA) emulsion, and Peg-IFN α-2a was used for the treatment of EAE. During the course of the study, clinical evaluation was assessed, and on day 21 post-immunisation blood samples were taken from the heart of mice for evaluation of IL-6, and enzymatic and non-enzymatic antioxidants. The mice were sacrificed and the brains and cerebellums were removed for histological analysis.

Results
Our findings indicated that Peg-IFN α-2a had beneficial effects on EAE by attenuation of the severity and a delay in the onset of disease. Histological analysis showed that treatment with Peg-IFN α-2a can reduce inflammation criteria. Moreover, in Peg-IFN α-2a-treated mice the serum level of IL-6 was significantly less than in controls, and total antioxidant capacity was significantly more than in the control animals.

Conclusions
These data indicate that Peg-IFN α-2a as an anti-serine protease with immunomodulatory properties may be useful for the treatment of MS.

keywords:

Therapeutic effects of pegylated-interferon-α2a in a mouse model of multiple sclerosis

Sanaz Afraei , Reza Sedaghat , Farzaneh Tofighi Zavareh , Zahra Aghazadeh , Parvin Ekhtiari , Gholamreza Azizi , Abbas Mirshafiey

experimental autoimmune encephalomyelitis, multiple sclerosis, antioxidant, Peg interferon alpha 2a

Sanaz Afraei

,

Reza Sedaghat

,

Farzaneh Tofighi Zavareh

,

Zahra Aghazadeh

,

Parvin Ekhtiari

,

Gholamreza Azizi

,

Abbas Mirshafiey